EUCTR2005-003416-30-IT进行中（未招募）不适用
Phase II study of Dacarbazine with the anti-vascular endothelial growth factor antibody (Bevacizumab) in patients with unresectable/metastatic melanoma. - Avastin+DTIC in Melanoma
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ROCHE
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Histologically or cytologically confirmed cutaneous malignant melanoma 2. Clinical evidence of metastatic disease and/or unresectable regional lymphatic disease and/or extensive in transit recurrent disease 3. Age = 18 4. ECOG Performance Status 0-1 5. Life expectancy of at least 12 weeks 6. Measurable and/or evaluable lesions according to RECIST criteria 7. Laboratory requirements: - Neutrophils =1.5 x 109/L and Platelets =100 x 109/L - Total bilirubin =1.5 time the upper-normal limits (UNL) of the Institutional normal values and ASAT (SGOT) and/or ALAT (SGPT) =2.5 x UNL, or =5 x UNL in case of liver metastases, alkaline phosphatase =2.5 x UNL, = 5 x UNL in case of liver metastases, =10 x UNL in case of bone metastases. - Creatinine clearance >50 mL/min or serum creatinine =1.5 x UNL) - Urine dipstick of proteinuria <2+. Patients discovered to have =2+ proteinuria on dipstick urinalysis at baseline, should undergo a 24-hour urine collection and must demonstrate =1 g of protein/24 hr. 8. Written informed consent. 9. Patients must be accessible for treatment and follow up. Patients registered on this trial must be treated and followed at the participating center
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 26
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 13
排除标准
- •1. At least 4 weeks since prior adjuvant therapy with interferon alfa 2. Prior interferon alfa and/or cytokine therapy (e.g., high dose interleukin-2) for metastatic disease 3. Prior investigational antiangiogenic agents 4. Prior chemotherapy regimen for metastatic disease 5. Radiotherapy to any site within 4 weeks before the study. 6. Symptomatic and/or unstable pre-existing brain metastases (CT or MRI of the head is required within 4 weeks prior to treatment start). 7. History of inflammatory bowel disease and/or acute/subacute bowel occlusion. 8. Serious non-healing wound or ulcer. 9. Evidence of bleeding diathesis or coagulopathy. 10. Uncontrolled hypertension. 11. Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (=6 months), myocardial infarction (= 6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication. 12. Current or recent (within 10 days prior to study treatment start) ongoing treatment with anticoagulants for therapeutic purposes. 13. Chronic, daily treatment with high-dose aspirin (>325 mg/day) or other medications known to predispose to gastrointestinal ulceration. 14. Patients with known allergy to Chinese hamster ovary cell proteins, or any of the components of the study medications 15. Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ 16. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study. 17. Pregnant or lactating women. Women of childbearing potential with either a positive or no pregnancy test at baseline. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study.
研究者
相似试验
已完成
2 期
A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic MelanomaMalignant MelanomaNCT01164007Hoffmann-La Roche40
进行中（未招募）
不适用
DETECT-01 DETICENE EVALUATION FOR COLORECTAL CANCER THERAPYEUCTR2011-002080-21-ITAZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE)
进行中（未招募）
1 期
Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy (PROMIT)MedDRA version: 20.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864MelanomaEUCTR2017-003556-23-DEniversity Hospital of the Friedrich-Alexander University Erlangen-Nürnberg38
未知
2 期
Phase 2 Study of Ipilimumab Plus DTIC in Japanese Advanced Melanoma PatientsMelanomaJPRN-jRCT2080221931Bristol-Myers K.K.26
尚未招募
不适用
A phase II study of daratumumab in combination with bortezomib and dexamethasone in patients with multiple myeloma who received 1 prior line of therapyKCT0004352Samsung Medical Center26